SLXP SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015 -- SLXP

NEW YORK, Nov. 24, 2014 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals, Ltd. ("Salix" or the "Company") SLXP securities between November 8, 2013 and November 6, 2014.

For more information, click here: http://zlk.9nl.com/salix-slxp.

The Complaint alleges that the Company made false and misleading statements and/or concealed material information regarding deteriorating demand and increasing inventory levels for Xifaxan and other Salix drugs.

On November 6 and November 7, 2014, Salix disclosed that its Chief Financial Officer had resigned, its wholesaler inventory levels were three times greater than previously reported, and that its previously-issued guidance for full-year 2014 revenues would not be met and would be drastically reduced.

If you suffered a loss in Salix you have until January 6, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/salix-slxp.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C.  The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits.  Attorney advertising. Prior results do not guarantee similar outcomes.